Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of SNX-1012 in the Treatment of Oral Mucositis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00385515
Recruitment Status : Completed
First Posted : October 9, 2006
Results First Posted : March 18, 2009
Last Update Posted : May 7, 2009
Sponsor:
Information provided by:
Mucosal Therapeutics

Brief Summary:
Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT) regimens and by radiation to the head and neck. The purpose of this study is to determine the effectiveness of SNX-1012 in decreasing the duration of Grade 2, 3, or 4 oral mucositis (OM) according to World Health Organization (WHO) criteria.

Condition or disease Intervention/treatment Phase
Stomatitis Oral Mucositis Drug: SNX-1012 (meclocycline sulfosalicylate) Drug: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer
Study Start Date : June 2006
Actual Primary Completion Date : May 2008
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1
SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days
Drug: SNX-1012 (meclocycline sulfosalicylate)
tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days

Placebo Comparator: 2
placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days
Drug: placebo
Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days




Primary Outcome Measures :
  1. Duration of Ulcerative Oral Mucositis [ Time Frame: At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle ]

Secondary Outcome Measures :
  1. Number of Participants With Ulcerative Oral Mucositis [ Time Frame: At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • Naive to focal radiation therapy in the head and neck regions for cancer prior to CT Cycle 1. Subjects with prior or concomitant radiation therapy to areas other than the head and neck may be enrolled.
  • Histologically confirmed diagnosis of breast or lung cancer (NSCLC or SCLC)
  • Chemotherapy regimen containing AC ± T or EC ± T (for breast cancer), cisplatin or carboplatin (for NSCLC or SCLC), or doxorubicin (for SCLC)
  • Subjects will receive the same regimen and dose of CT in the OM Treatment CT Cycle as was administered in the immediately preceding CT Cycle.
  • Subjects will have had OM of WHO Grade of greater than or equal to 2 during CT Cycle 1 or Cycle 2
  • Subjects 18 years and older
  • Karnofsky Performance Score >=60
  • Baseline laboratory assessments:

Hemoglobin (Hgb) level >= 9 g/dL Absolute neutrophil count (ANC) >= 1.5 x 10 to the 9/L Platelet count >= 100 x 10 to the 9/L Serum bilirubin level <= 1.5 times institutional upper limit of normal (ULN) Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level <= 2 times above ULN

  • Females of childbearing potential must have a negative serum or urine pregnancy test result at the screening visit prior to the start of Cycle 1 and at the visit scheduled for <= 48 hours prior to the start of the OM Treatment CT Cycle
  • Subjects with reproductive capability must agree to practice adequate contraception methods (males must use condoms or be surgically sterilized; females must be surgically sterilized, post-menopausal for at least 1 year, or use an appropriate double barrier method, prescribed birth control oral contraceptive, patch, implant, or injection during the course of the study and for up to 30 days after completion of study assessments)
  • Absence of other serious concurrent medical illness
  • Psychologically able to participate and comply with study requirements

Exclusion Criteria:

  • Prior history of oral mucositis with previous chemotherapy treatment
  • Previous treatment with an anthracycline agent (other than low-dose neoadjuvant therapy)
  • Active liver disease or serum AST and/or ALT level > 2 times above ULN
  • Currently receiving an investigational agent, planning to receive an investigational agent during the study period, or received an investigational agent within 30 days of the first dose of SNX-1012
  • Use of an immunosuppressive regimen of systemic corticosteroids
  • Unwilling/unable to receive periodic oral assessments by a study evaluator or unable to complete the daily self-reported outcome questionnaire
  • Pregnant or breast-feeding women
  • Bronchoalveolar carcinoma
  • Metastases to the central nervous system
  • Prior or planned focal radiation therapy in the head or neck regions for the treatment of cancer (prior radiation to areas other than the head and neck is permitted)
  • Presence of active or history of chronic oral mucosal disease
  • Presence or history of any other primary malignancy (curatively treated nonmelanoma skin cancer is allowed)
  • History of chronic liver disease
  • Active hepatitis A or B
  • Unable to receive CT during the OM Treatment CT Cycle at the same regimen and/or dose as in the immediately preceding CT cycle.
  • Known sensitivity to tetracyclines
  • Known to be seropositive for HIV or HCV
  • Use of an immunosuppressive regimen of systemic corticosteroids.
  • Current alcohol dependence or drug abuse
  • Psychological, social or familial or geographical reasons that would hinder or prevent study visits
  • Compromised ability to give written informed consent and/or to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00385515


Locations
Show Show 27 study locations
Sponsors and Collaborators
Mucosal Therapeutics

Layout table for additonal information
Responsible Party: Marna Doucette, Coserics
ClinicalTrials.gov Identifier: NCT00385515    
Other Study ID Numbers: SNX-1012-CLN2-006
First Posted: October 9, 2006    Key Record Dates
Results First Posted: March 18, 2009
Last Update Posted: May 7, 2009
Last Verified: April 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucositis
Stomatitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Meclocycline
Anti-Bacterial Agents
Anti-Infective Agents